Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial, and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a large portfolio of Phase I-III clinical studies including immunotherapy for gynaecological malignancies. In this video, she speaks about Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.
This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The homologous recombination (HR) status of tumor samples will be used to assess therapy response.